Orexin A vs Orexin B
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Hypocretin-1, Hcrt-1
Orexin A (also called hypocretin-1) is a 33-amino-acid brain peptide made by a small cluster of neurons in the hypothalamus, and it is one of the main signals that keeps you awake. People with narcolepsy type 1 have lost most of these neurons, and orexin is undetectable in their spinal fluid. Orexin A itself is not an approved drug, but a few small German studies have sprayed it into the nose of narcolepsy patients and healthy men with measurable effects. Interesting science, very early stage.
Also: Hypocretin-2, Hcrt-2
Orexin B (hypocretin-2) is the sister peptide of orexin A. Both are cut from the same precursor protein in the hypothalamus and both help regulate wakefulness and appetite. Orexin B is a 28-amino-acid linear peptide that mostly acts through the OX2R receptor, the receptor most tied to narcolepsy. The catch for anyone hoping to use it: it falls apart fast in the blood, barely reaches the brain from the bloodstream, and has never been given to humans in a published study.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Orexin A has stronger research evidence (Human Trials) compared to Orexin B (Preclinical).
Detailed Comparison
| Attribute | Orexin A | Orexin B |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Orexin A activates both orexin receptors (OX1R and OX2R) with high affinity. Those receptors sit on brainstem and hypothalamic arousal centers (the histamine, noradrenaline, dopamine and acetylcholine systems), so orexin acts like a stabilizer that keeps the brain locked in the wake state and stops it slipping into REM sleep at the wrong time. Losing it causes narcolepsy: orexin knockout mice and dogs with a broken OX2R gene both develop narcolepsy, and giving orexin A into the brain of narcoleptic mice suppressed cataplexy. Orexin also drives appetite and raises sympathetic nerve activity. A mouse study found orexin A crosses the blood-brain barrier fairly well, and the nasal route is used in humans to deliver more of it to the brain. | Orexin B binds OX2R about as strongly as orexin A does, but binds OX1R roughly 20 times more weakly, so it behaves as a relatively OX2R-preferring signal. OX2R is the receptor that matters most for staying awake and keeping REM sleep in its place: a broken OX2R gene causes inherited narcolepsy in dogs, and the newest approved narcolepsy drug is an OX2R agonist. Structurally, orexin B is a linear chain without the two disulfide bridges that make orexin A more stable. A 1999 mouse study found that injected orexin B was rapidly degraded in blood and none reached the brain intact, while orexin A crossed easily. That is the main reason human research has focused on orexin A. |
| Common Dosing | 435 nmol (about 1.5 mg) intranasal Single dose in studies | No established human dose Not established |
| Administration | Intranasal spray | Intracerebroventricular or local injection in animal studies |
| Typical Duration | Single doses only in published human studies | Acute single-dose animal experiments |
| Best Time to Take | Morning | Not established |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The human data comes from a handful of small, placebo-controlled crossover studies, mostly from one group in Kiel, Germany. In 2008, intranasal orexin A improved smell detection thresholds in 7 narcolepsy patients. In 2011, a single 435 nmol nasal dose before bed in 8 patients did not change nighttime wakefulness but reduced REM sleep and wake-to-REM transitions. In 2014, the same dose given in the morning to 14 patients reduced wake-REM transitions and improved divided attention (fewer errors). In 2022, 500 nmol in 10 healthy men acutely raised sympathetic nerve activity to blood vessels, without changing blood pressure or heart rate. In sleep-deprived monkeys, nasal orexin A reversed some of the drop in memory performance (Deadwyler, 2007). That is the whole human record: single doses, tiny groups, short-term outcomes. The real clinical action has moved to small-molecule drugs that mimic orexin at OX2R. Takeda's oveporexton (brand name Orzeyful) was FDA-approved on August 5, 2026 for narcolepsy type 1, which validates the target but is not the same thing as using the peptide. | Orexin B has been studied for almost 30 years, but almost entirely as a research tool in animals and tissue. The 1998 discovery paper in Cell (Sakurai and colleagues) showed both orexins increased food intake when injected into rat brains. Work since then has mapped its role in arousal, feeding, and more recently pain: 2026 mouse research found orexin B acting at OX2R could trigger migraine-like headache pain in male but not female mice. We could not find any published study giving orexin B to humans, by nose or by injection, and no registered clinical trials. If you want the orexin story with actual human data, see orexin A. Orexin B on its own is a preclinical compound with a real biological role and no tested human use. |
Frequently Asked Questions: Orexin A vs Orexin B
What is the difference between Orexin A and Orexin B?
Orexin A is a cognitive peptide that orexin a (also called hypocretin-1) is a 33-amino-acid brain peptide made by a small cluster of neurons in the hypothalamus, and it is one of the main signals that keeps you awake. people with narcolepsy type 1 have lost most of these neurons, and orexin is undetectable in their spinal fluid. orexin a itself is not an approved drug, but a few small german studies have sprayed it into the nose of narcolepsy patients and healthy men with measurable effects. interesting science, very early stage. Orexin B is a cognitive peptide that orexin b (hypocretin-2) is the sister peptide of orexin a. both are cut from the same precursor protein in the hypothalamus and both help regulate wakefulness and appetite. orexin b is a 28-amino-acid linear peptide that mostly acts through the ox2r receptor, the receptor most tied to narcolepsy. the catch for anyone hoping to use it: it falls apart fast in the blood, barely reaches the brain from the bloodstream, and has never been given to humans in a published study. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Orexin A or Orexin B?
Neither is universally "better" - the choice depends on your specific goals. Orexin A is typically used for cognitive purposes, while Orexin B is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Orexin A and Orexin B be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Orexin A and Orexin B together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.